MAPT and familial pancreatic carcinoma: In pancreatic cancer, MAPT has been recognized as a predictive marker of the treatment effect of sulfur benzoylphenylurea analogs (SG410 and SG430), and the methylation of MAPT in plasma has been detected for the noninvasive diagnosis of pancreatic cancer [30,31].